Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iron Isomaltoside vs Iron Sucrose for Pregnancy Anemia
NCT05251493Phase 3Recruiting
- Sponsor
- Saskatchewan Health Authority
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Saskatchewan Health Authority. Primary endpoints: Correction of anemia (Hb >= 110 g/L), Correction of anemia at delivery and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05251493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251493.